Literature DB >> 28552463

Incremental cost-effectiveness ratio and net monetary benefit: Current use in pharmacoeconomics and future perspectives.

Sabrina Trippoli1.   

Abstract

Mesh：

Year:  2017        PMID： 28552463     DOI： 10.1016/j.ejim.2017.05.015

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN： 0953-6205            Impact factor:   4.487


× No keyword cloud information.
  6 in total

1.  Willingness-to-Pay and Benefit-Cost Analysis of IPL for Rosacea Treatment: A Cross-Sectional Study in China.

Authors:  Qing Deng; Shu-Ping Zhang; Yu-Xuan Deng; Fang-Fen Liu; Wei Shi; Hong-Fu Xie; Yi Xiao; Ying-Xue Huang; Ji Li
Journal:  Patient Prefer Adherence       Date:  2020-10-09       Impact factor: 2.711

Review 2.  Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR + breast cancer and negative axillary ultrasound.

Authors:  Aubriana M McEvoy; Steven Poplack; Katelin Nickel; Margaret A Olsen; Foluso Ademuyiwa; Imran Zoberi; Elizabeth Odom; Jennifer Yu; Su-Hsin Chang; William E Gillanders
Journal:  Breast Cancer Res Treat       Date:  2020-07-10       Impact factor: 4.872

3.  Handling the procurement of prostheses for total hip replacement: description of an original value based approach and application to a real-life dataset reported in the UK.

Authors:  Andrea Messori; Sabrina Trippoli; Claudio Marinai
Journal:  BMJ Open       Date:  2017-12-19       Impact factor: 2.692

4.  Value-based procurement of prostheses for total knee replacement.

Authors:  Andrea Messori; Sabrina Trippoli
Journal:  Orthop Rev (Pavia)       Date:  2018-02-16

5.  Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis.

Authors:  Shuyan Gu; Lizheng Shi; Hui Shao; Xiaoyong Wang; Xiaoqian Hu; Yuxuan Gu; Hengjin Dong
Journal:  BMC Med       Date:  2020-12-03       Impact factor: 8.775

6.  Fexapotide triflutate vs oral pharmacotherapy as initial therapy for moderate-to-severe benign prostate hyperplasia patients: a cost-effectiveness analysis.

Authors:  Yifan Wei; Joel W Hay; Alan R Hay; Sze-Chuan Suen
Journal:  BMC Urol       Date:  2022-05-13       Impact factor: 2.090
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.